- Home
- GLPG
GLPG
Galapagos NV
as 12-20-2024 4:00pm EST
| Founded: | 1999 | Country: | Belgium |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | 2005 |
| Target Price: | $30.75 | AVG Volume (30 days): | 191.8K |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $24.16 - $42.46 | Next Earning Date: | 02-12-2025 |
| Revenue: | $290,089,226 | Revenue Growth: | -52.19% |
| Revenue Growth (this year): | 28.34% | Revenue Growth (next year): | -9.15% |
Latest Galapagos NV News
GLPG Breaking Stock News: Dive into GLPG Ticker-Specific Updates for Smart Investing
Simply Wall St.
10 days ago
Galapagos NV (AMS:GLPG) stock most popular amongst retail investors who own 56%, while public companies hold 25%
Clinical Trials Arena
12 days ago
ASH 2024: Galapagos presents positive results for a seven-day ‘vein-to-vein’ CAR T-cell therapy
GlobeNewswire
15 days ago
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
GlobeNewswire
2 months ago
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024
Simply Wall St.
2 months ago
Galapagos Third Quarter 2024 Earnings: €0.74 loss per share (vs €0.39 profit in 3Q 2023)
GuruFocus.com
2 months ago
Galapagos NV (GLPG) Q3 2024 Earnings Call Highlights: Strong Cash Position and R&D Progress ...
GlobeNewswire
2 months ago
Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update
GuruFocus.com
2 months ago
EcoR1 Capital, LLC Increases Stake in Galapagos NV
Compare GLPG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GLPG Galapagos NV - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.